Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis.
نویسندگان
چکیده
Primary myelofibrosis (PMF) is a clonal hematologic malignancy characterized by BM fibrosis, extramedullary hematopoiesis, circulating CD34+ cells, splenomegaly, and a propensity to evolve to acute myeloid leukemia. Moreover, the spleen and BM of patients harbor atypical, clustered megakaryocytes, which contribute to the disease by secreting profibrotic cytokines. Here, we have revealed that megakaryocytes in PMF show impaired maturation that is associated with reduced GATA1 protein. In investigating the cause of GATA1 downregulation, our gene-expression study revealed the presence of the RPS14-deficient gene signature, which is associated with defective ribosomal protein function and linked to the erythroid lineage in 5q deletion myelodysplastic syndrome. Surprisingly, reduced GATA1 expression and impaired differentiation were limited to megakaryocytes, consistent with a proproliferative effect of a GATA1 deficiency on this lineage. Importantly, expression of GATA1 effectively rescued maturation of PMF megakaryocytes. Together, these results suggest that ribosomal deficiency contributes to impaired megakaryopoiesis in myeloproliferative neoplasms.
منابع مشابه
P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis.
Splenomegaly is a major manifestation of primary myelofibrosis (PMF) contributing to clinical symptoms and hematologic abnormalities. The spleen from PMF patients contains increased numbers of hematopoietic stem cells (HSC) and megakaryocytes (MK). These MK express high levels of P-selectin (P-sel) that, by triggering neutrophil emperipolesis, may cause TGF-β release and disease progression. Th...
متن کاملCD133 marks a stem cell population that drives human primary myelofibrosis.
Primary myelofibrosis is a myeloproliferative neoplasm characterized by bone marrow fibrosis, megakaryocyte atypia, extramedullary hematopoiesis, and transformation to acute myeloid leukemia. To date the stem cell that undergoes the spatial and temporal chain of events during the development of this disease has not been identified. Here we describe a CD133(+) stem cell population that drives th...
متن کاملHEMATOPOIESIS AND STEM CELLS Characterization of the TGF-b1 signaling abnormalities in the Gata1 mouse model of myelofibrosis
Department of Medicine, Campus Biomedico, and Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy; Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY; Myeloproliferative Disease Research Consortium, New York, NY; Service for Biotechnology and Animal Welfare, Istituto Superiore di Sanità, Rome, Italy; Policlinico San Matteo, Pavi...
متن کاملA pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-beta1 in the development of myelofibrosis.
Idiopathic myelofibrosis (IM) is a disease characterized by marrow fibrosis, abnormal stem/progenitor cell trafficking, and extramedullary hematopoiesis frequently associated with alterations in megakaryocytes (Mks). Mice harboring genetic alterations in either the extrinsic (ectopic thrombopoietin expression, TPO(high) mice) or intrinsic (hypomorphic GATA-1 mutation, GATA-1(low) mice) control ...
متن کاملThe N-terminal domain of human GATA1 prevents dyserythropoietic anemia and megakaryocyte dysplasia in vivo
Inherited mutations in the X-linked hematopoietic transcription factor GATA1 lead to a wide range of blood disorders, from Diamond-Blackfan anemia to myelodysplastic syndrome. Alternative splicing produces two functionally distinct isoform of GATA1: full-length GATA1 and short GATA1 (GATA1s), which lacks the Nterminal activity-regulating module. The in vivo role of the N-terminal GATA1 domain i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Journal of clinical investigation
دوره 127 4 شماره
صفحات -
تاریخ انتشار 2017